


ANAVEON® Information Pack, August 2021



Basel

Anaveon is a spin-out from University of Zurich and Novartis, founded in Switzerland in 2018 by experts in the field of immuno-therapy

Lead program is ANV419, an IL-2 / anti-IL-2 antibody fusion protein which potently and selectively signals through the β/γ receptor

ANV419 is a clinical stage (Ph I) β/γ agonist promoting strong proliferation of NK and CD8⁺ T cells but not Tregs

Strong pharmacodynamic effects, exceptional safety/tolerability and long *in vivo* half life support a best-in-class potential for ANV419 in the field of selective β/γ therapeutics

Clinical development in both solid tumors and hematologic malignancies is designed to identify the full range of clinical benefits of β/γ signalling in multiple indications

Anaveon is well positioned to be a leader in the field of engineered IL-2 and therapeutic cytokines

Second development compound, ANV600 delivers selective β/γ signalling to anti-tumor cells and has expanded therapeutic potential

Discovery programs in engineered cytokines can potentially significantly widen the company scope



R&D team has deep experience in immunology, oncology, pharmaceutical development and demonstrated ability to rapidly advance new concepts to clinical proof of concept

From Proleukin® to ANV419



Proleukin®



Signals through:



- Lack of selectivity
- Dose-limiting toxicity
- Short *in vivo* half-life

ANV419

Signals through:




- Excellent selectivity for effector cells
- Good therapeutic window
- Extended half-life

Our lead compound ANV419 is selective by design



ANV419 was designed to selectively redirect IL-2 in three steps:


- Generation of anti-IL-2 antibodies
 - Highly specific antibodies were selected to permit binding to IL-2R β/γ and block binding to IL-2R α
- Selection of the lead antibody
 - Optimal pharmacodynamic and pharmacokinetic properties (affinity and off-rate)
 - Humanisation
- Fusion of the antibody and IL-2



Anaveon's pipeline based on engineered cytokines



Anaveon is exploiting the power of cytokines to orchestrate immune responses through safe and effective treatments for a variety of serious diseases. Our pipeline reflects this: we are developing a unique no-alpha IL-2 portfolio with broad potential in tumor immunotherapy.



Anaveon is developing a unique no-alpha IL-2 portfolio with broad potential in tumor immunotherapy. We are using our expertise in cytokines to deliver new investigational therapies for diseases with immune etiopathology.

Our team of dedicated experts

Management



Andreas Katopodis, PhD, MBA
Chief Executive Officer

Co-founder of Anaveon with 26 years experience at Novartis and previously Ciba-Geigy. He was responsible for both early discovery and development programs and contributed to the development of LMW compounds and biologics for solid organ transplantation and auto-immunity. He led multiple programs in transplantation tolerance, including a cell therapy program for kidney tolerance currently in pivotal trials by Talaris Therapeutics.



Christoph Huber, PhD
Chief Scientific Officer

Over 10 years experience in drug R&D. Before joining Anaveon, he headed Roche immunosafety in Basel and co-lead the strategy to reduce immunogenicity in the Roche portfolio. Previously he held leadership positions at Pfizer Vaccine Immunotherapeutics working on oncology and non-oncology vaccine therapy programs and COI Pharmaceuticals where he established a program for tumor recognition by NK cells.



Christoph Bucher, MD
Chief Medical Officer

Experienced attending physician with board certification in internal medicine and hematology. Over 8 years experience in clinical development in immunology and stem cell transplantation at Roche and Novartis. He has designed and successfully executed first-in-man studies for multiple compounds and cell therapy products. He practices Hematology part time at the University Hospital of Basel.

Contact us

We look forward to hearing from you

Email

julia.wilson@anaveon.com

Postal Address

Anaveon AG
Technologiepark Basel
Hochbergerstrasse 60C
4057 Basel
Switzerland

www.anaveon.com

